In conclusion, the treatment of Roflumilast is able to re-activate cAMP/PKA/CREB signaling axis in ovarian cancer, leading to FtMt-mediated tumor inhibition in vitro and vivo. Therefore, the application of PDE inhibitors for cancer merits consideration in clinical. This evidence concerns the gene ALDH7A1 and ovarian carcinoma.